These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8422738)

  • 21. [Parkinson's disease: modern evolution].
    Guillard A
    Soins; 1993 May; (572):8-11. PubMed ID: 8303420
    [No Abstract]   [Full Text] [Related]  

  • 22. Rational management of the 'on-off' syndrome in Parkinson's disease.
    Coleman RJ
    Q J Med; 1990 Feb; 74(274):121-31. PubMed ID: 2189148
    [No Abstract]   [Full Text] [Related]  

  • 23. Basal ganglia, Parkinson's disease and levodopa therapy. Proceedings of a meeting. St Thomas, Virgin Islands, January 2000.
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S1-126. PubMed ID: 11221749
    [No Abstract]   [Full Text] [Related]  

  • 24. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
    Fernandez HH; Odin P
    Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Ferreira JJ
    Neurodegener Dis Manag; 2016 Oct; 6(5):349-62. PubMed ID: 27599671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of dopaflex on the clinical picture and reaction time of parkinsonian patients.
    Antal J
    Ther Hung; 1974; 22(2):70-8. PubMed ID: 4419534
    [No Abstract]   [Full Text] [Related]  

  • 27. Balance and Gait Represent Independent Domains of Mobility in Parkinson Disease.
    Horak FB; Mancini M; Carlson-Kuhta P; Nutt JG; Salarian A
    Phys Ther; 2016 Sep; 96(9):1364-71. PubMed ID: 27034314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levodopa unresponsive symptoms in Parkinson disease.
    Sethi K
    Mov Disord; 2008; 23 Suppl 3():S521-33. PubMed ID: 18781679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current status of clinical pharmacology training in the United States.
    Peck CC; Crout JR
    Clin Pharmacol Ther; 1986 Apr; 39(4):451-8. PubMed ID: 3956065
    [No Abstract]   [Full Text] [Related]  

  • 30. Parkinson's disease. The L-dopa era.
    Yahr MD
    Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
    [No Abstract]   [Full Text] [Related]  

  • 31. [Parkinson disease--a movement disorder].
    Fortschr Neurol Psychiatr; 1997 Apr; 65(4 Suppl Morbus):1-4. PubMed ID: 9330648
    [No Abstract]   [Full Text] [Related]  

  • 32. [Current approaches in the treatment of Parkinson disease].
    Caraceni T; Geminiani G; Tamma F
    Recenti Prog Med; 1989 Dec; 80(12):686-91. PubMed ID: 2576471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and pathophysiologic aspects of late levodopa failure.
    Poewe W
    Neurology; 1993 Dec; 43(12 Suppl 6):S28-30. PubMed ID: 8264908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacologists for the future in the United Kingdom.
    McDevitt DG
    Clin Pharmacol Ther; 1986 Apr; 39(4):459-61. PubMed ID: 3956066
    [No Abstract]   [Full Text] [Related]  

  • 35. Patient page. Slowing down a "slow" movement disorder: selegiline's benefit in treating Parkinson disease.
    Lo SE; Jain S
    Neurology; 2006 Apr; 66(8):E28-9. PubMed ID: 16636224
    [No Abstract]   [Full Text] [Related]  

  • 36. Parkinson's disease.
    Clarke CE; Moore AP
    Am Fam Physician; 2007 Apr; 75(7):1045-8. PubMed ID: 17427619
    [No Abstract]   [Full Text] [Related]  

  • 37. [Cerebral hemodynamics and clinical pharmacology in Parkinson disease].
    Marc-Vergnes JP; Celsis P; Montastruc JL; Demonet JF; Agniel A; Rascol O; Viallard G; Doyon B; Rascol A
    Therapie; 1988; 43(2):83-8. PubMed ID: 3406932
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of levodopa treatment on contrast sensitivity in Parkinson's disease.
    Bulens C; Meerwaldt JD; Van der Wildt GJ; Van Deursen JB
    Ann Neurol; 1987 Sep; 22(3):365-9. PubMed ID: 3674801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease.
    Chen H; Fang J; Li F; Gao L; Feng T
    Neurol Sci; 2015 Jul; 36(7):1217-23. PubMed ID: 25616444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. l-dopa-induced off: Functional overlay in Parkinson disease.
    Erro R; Bozzetti S; Goffi F; Mariotto S; Tinazzi M
    J Neurol Sci; 2016 Jun; 365():1-2. PubMed ID: 27206863
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.